SGB Reduces the Incidence and Severity of CSA-AKI
Launched by YANGZHOU UNIVERSITY · Dec 5, 2022
Trial Information
Current as of January 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of any gender were eligible provided they were between the ages of 18 and 80 years
- • 2. American Society of Anesthesiologists (ASA) class of Ⅱ or Ⅲ.
- Exclusion Criteria:
- • 1. emergency cardiac surgery;
- • 2. major vascular surgery;
- • 3. non-sinus rhythm, reoperation;
- • 4. contraindications for TEE or SGB;
- • 5. abnormal preoperative renal function;
- • 6. severe preoperative heart failure with left ventricular ejection fraction \< 30%, multi-organ dysfunction;
- • 7. and severe infection requiring continuous antibiotic treatment;
- • 8. enrolled in another clinical trial.
- Elimination criteria:
- • 1. incomplete follow-up data;
- • 2. withdrawal during the procedure;
- • 3. SGB failure or complications;
- • 4. insufficient ultrasonographic imaging of the left renal artery on TEE;
- • 5. repeated CPB during surgery;
- • 6. need for cardiac assist devices (extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist devices) after CPB completion.
About Yangzhou University
Yangzhou University is a prestigious educational and research institution located in Yangzhou, China, dedicated to advancing knowledge and innovation in various fields, including medicine and healthcare. As a clinical trial sponsor, Yangzhou University leverages its extensive academic resources and expertise to conduct high-quality research aimed at improving patient outcomes and contributing to the scientific community. The university fosters collaboration among multidisciplinary teams and emphasizes ethical practices and regulatory compliance in its clinical research endeavors, ensuring the integrity and reliability of its findings. Through its commitment to excellence, Yangzhou University strives to enhance the understanding of health-related issues and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yangzhou, Jiangsu, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials